Wire · operational-macro
Voceryq Submitted for EU Approval to Treat RRP
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 November 2026 · Fusion42 review
Inovio has submitted Voceryq for conditional marketing authorization to the European Medicines Agency to treat adults with recurrent respiratory papillomatosis, following its accelerated FDA approval in the US. Voceryq is a DNA-based immunotherapy aimed at reducing the need for repeated surgeries that risk damaging vocal cords and airway function.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 1 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
You gain access to a new treatment market in Europe with no current non-surgical options for RRP. Start planning your regulatory and clinical strategy for DNA-based therapies targeting rare respiratory conditions.
◆ Coverage
9 sources · first reported 1 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics